Improving attribution of adverse events in oncology clinical trials

Author:

George Goldy C.,Barata Pedro C.ORCID,Campbell Alicyn,Chen Alice,Cortes Jorge E.ORCID,Hyman David M.,Jones Lee,Karagiannis Thomas,Klaar Sigrid,Le-Rademacher Jennifer G.,LoRusso Patricia,Mandrekar Sumithra J.,Merino Diana M.,Minasian Lori M.,Mitchell Sandra A.,Montez Sandra,O'Connor Daniel J.,Pettit Syril,Silk Elaine,Sloan Jeff A.,Stewart Mark,Takimoto Chris H.,Wong Gilbert Y.,Yap Timothy A.,Cleeland Charles S.,Hong David S.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference35 articles.

1. Reducing the toxicity of cancer therapy: recognizing needs, taking action;Cleeland;Nat Rev Clin Oncol,2012

2. Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and critical path institute workshop;Kluetz;Value Health J. Int. Soc. Pharm. Outcomes Res.,2018

3. Streamlining adverse events reporting in oncology: an american society of clinical oncology research statement;Levit;J Clin Oncol,2018

4. FDA. Questions and answers on FDA's Adverse Event Reporting System (FAERS). 2018.

5. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies;Thanarajasingam;Lancet Haematol,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3